Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
GLAND

Gland Pharma Share Price

 

 

Gland Pharma live price: ₹2250. It opened at ₹2,315 vs previous close ₹2,313; intraday high/low: ₹2,338/₹2,230. The 50 & 200 DMA stand at ₹1,931.78/₹1,818.51.

Gland Pharma Performance

  • Today's Low
  • ₹2,230
  • Today's High
  • ₹2,338
  • 52 Week Low
  • ₹1,513
  • 52 Week High
  • ₹2,396
  • Open Price₹2,315
  • Previous Close₹2,313
  • Volume218,609
  • 50 DMA₹1,931.78
  • 100 DMA₹1,856.91
  • 200 DMA₹1,818.51

Gland Pharma Chart

Investment Returns

  • Over 1 Month + 29.38%
  • Over 3 Month + 23.48%
  • Over 6 Month + 27.87%
  • Over 1 Year + 42.57%

Smart Investing Starts Here Start SIP with Gland Pharma for Steady Growth!

Invest Now

Gland Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 36.1
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 37,070
  • P/B Ratio
  • 3.8
  • Average True Range
  • 87.63
  • EPS
  • 63.37
  • Dividend Yield
  • 0.8
  • MACD Signal
  • 120.57
  • RSI
  • 67.81
  • MFI
  • 91.3

Latest Stock News Updates

Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook

Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company's contract development and manufacturing business is also expanding. Investors are watching Gland Pharma's growth prospects.

Gland Pharma shares jump 16% to 52-week high on Q4; analysts retain 'Buy'

Sentiment was further buoyed by bullish brokerage commentary, with Elara Capital and Motilal Oswal Financial Services retaining Buy calls on Gland Pharma, citing strong earnings

Gland Pharma Results Earnings Call for Q4FY26 & Full Year

Conference Call with Gland Pharma Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

Gland Pharma Financials

Gland Pharma Technicals

EMA & SMA

Current Price
₹2,250.00
-63 (-2.72%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹2,096.32
  • 50 Day
  • ₹1,931.78
  • 100 Day
  • ₹1,856.91
  • 200 Day
  • ₹1,818.51

Resistance and Support

2272.5 Pivot Speed
  • R3 2,422.50
  • R2 2,380.00
  • R1 2,315.00
  • S1 2,207.50
  • S2 2,165.00
  • S3 2,100.00

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Gland Pharma Ltd., is a leading injectables manufacturer with a global presence across 60 countries. The company offers a wide range of complex injectables, focusing on sterile injectables, oncology, and ophthalmic products through a B2B model.

Gland Pharma has an operating revenue of Rs. 6,430.65 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 23% is great, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 26% and 25% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Gland Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-15 Audited Results & Final Dividend
2026-01-28 Quarterly Results
2025-11-03 Quarterly Results
2025-08-05 Quarterly Results
2025-05-20 Audited Results & Final Dividend
Date Purpose Remarks
2025-08-14 FINAL Rs.18.00 per share(1800%)Final Dividend
2024-08-16 FINAL Rs.20.00 per share(2000%)Final Dividend
View Gland Pharma Dividend History Arrow

Gland Pharma Shareholding Pattern

51.83%
31.78%
1.35%
7.29%
0%
2.54%
5.21%

About Gland Pharma

Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well. 

In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world. 
 

Products offered by Gland Pharma Ltd.

  • Anti Malarials
  • Anti-Infectives
  • Anti-Neoplastics
  • Blood Related
  • Cardiac
  • Gastro Intestinal
  • Gynaecological
  • Hormones
  • Neuro / Cns
  • Ophthal / Otologicals
  • Others
  • Pain / Analgesics
  • Respiratory
  • Vitamins / Minerals / Nutrients

 

Gland Pharma Ltd is listed on 2 exchanges, and these are:

  • National Stock Exchange of India Ltd.
  • The Stock Exchange, Mumbai


Included in Indices

  • NIFTY 50 - No 
  • NIFTY next 50 - YES
  • NIFTY 100 - YES
  • S&P BSE 200 - YES
  • S&P BSE 250 large midcap index- YES
  • S&P BSE finance- NO

Other listing information

  • Incorporation date - March 20 1978
  • BSE group - A 
  • BSE Code - 543245
  • NSE - GLANDEQ

1978
PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.

1994
From a private limited company, it becomes a public limited company.

1996
Becomes the first company to establish a PFS facility in India.

2000
Signs its first Contract Manufacturing agreement for regulated markets

2007
Enters the US market with Ketorolac PFS

2013
Entered European markets with Tirofiban
The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.

2016
In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.

2017
Fosun Pharma acquired a majority stake in the company.

2018
Enoxaparin injection received US market approval in 2018.
The first ophthalmic product has been approved for sale in the United States.

View More
  • NSE Symbol
  • GLAND
  • BSE Symbol
  • 543245
  • ISIN
  • INE068V01023

Similar Stocks to Gland Pharma

Gland Pharma FAQs

Gland Pharma share price is ₹2,250 As on 30 May, 2026 | 17:27

The Market Cap of Gland Pharma is ₹37070.2 Cr As on 30 May, 2026 | 17:27

The P/E ratio of Gland Pharma is 36.1 As on 30 May, 2026 | 17:27

The PB ratio of Gland Pharma is 3.8 As on 30 May, 2026 | 17:27

Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

The ROE of Gland Pharma Limited is 16% is which good.

Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd. 

  • Cipla 
  • Sun Pharma 
  • Pfizer 
  • Lupin
  • Eris Life 
  • Aarti Drugs 
  • Hester Bio
  • RPG Life 
  • Bafna Pharma 
  • Jb Chemicals 

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23